advertisement
Medeiros FA 21
Showing records 1 to 21 | Display all abstracts from Medeiros FA106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Mariottoni EB
Ophthalmology. Glaucoma 2023; 6: 228-238
106745 Validation of Rates of Mean Deviation Change as Clinically Relevant End Points for Glaucoma Progression
Medeiros FA
Ophthalmology 2023; 130: 469-477
105743 Comparison of 10-2 and 24-2 Perimetry to Diagnose Glaucoma Using OCT as an Independent Reference Standard
Onyekaba NE
Ophthalmology. Glaucoma 2023; 6: 187-197
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Weinreb RN
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106745 Validation of Rates of Mean Deviation Change as Clinically Relevant End Points for Glaucoma Progression
Jammal AA
Ophthalmology 2023; 130: 469-477
106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Datta S
Ophthalmology. Glaucoma 2023; 6: 228-238
105743 Comparison of 10-2 and 24-2 Perimetry to Diagnose Glaucoma Using OCT as an Independent Reference Standard
Estrela T
Ophthalmology. Glaucoma 2023; 6: 187-197
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Bacharach J
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Shigueoka LS
Ophthalmology. Glaucoma 2023; 6: 228-238
105743 Comparison of 10-2 and 24-2 Perimetry to Diagnose Glaucoma Using OCT as an Independent Reference Standard
Naithani R
Ophthalmology. Glaucoma 2023; 6: 187-197
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Brubaker JW; Medeiros FA
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
105743 Comparison of 10-2 and 24-2 Perimetry to Diagnose Glaucoma Using OCT as an Independent Reference Standard
McCarthy KM
Ophthalmology. Glaucoma 2023; 6: 187-197
106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Jammal AA
Ophthalmology. Glaucoma 2023; 6: 228-238
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Bejanian M
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Tavares IM
Ophthalmology. Glaucoma 2023; 6: 228-238
105743 Comparison of 10-2 and 24-2 Perimetry to Diagnose Glaucoma Using OCT as an Independent Reference Standard
Jammal AA; Medeiros FA
Ophthalmology. Glaucoma 2023; 6: 187-197
106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Henao R
Ophthalmology. Glaucoma 2023; 6: 228-238
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Bernstein P
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Carin L
Ophthalmology. Glaucoma 2023; 6: 228-238
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Robinson MR
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106413 Deep Learning-Assisted Detection of Glaucoma Progression in Spectral-Domain OCT
Medeiros FA
Ophthalmology. Glaucoma 2023; 6: 228-238
